Investigational acasunlimab (duobody® -pd-l1x4-1bb) in combination with pembrolizumab demonstrates meaningful clinical activity in phase 2 trial in patients with previously treated metastatic non-small cell lung cancer (mnsclc)

Copenhagen, denmark & mainz, germany--(business wire)--genmab a/s (nasdaq: gmab) and biontech se (nasdaq: bntx) today announced initial data from the phase 2 gct1046-04 trial (nct05117242) evaluating acasunlimab (duobody-pd-l1x4-1bb), an investigational bispecific antibody also known as gen1046/bnt311, as monotherapy and in combination with pembrolizumab in patients with pdl(1)-positive mnsclc who had disease progression following one or more prior lines of anti-pd(l)1 containing treatment. the.
BNTX Ratings Summary
BNTX Quant Ranking